Investors might want to bet on Sage Therapeutics, Inc. (SAGE), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...

Dalzanemdor has failed as a treatment for cognitive impairment in Alzheimer's, Parkinson's and now Huntington's diseases Sage Therapeutics Inc.'s stock (SAGE) fell 2.4% Wednesday, headed for a fresh ...

More than 165 jobs to go as company seeks to extend cash runway and focus on postpartum drug launch Sage Therapeutics Inc.'s stock slid 4.7% Thursday, after the biotech said it's cutting about 33% of ...

Sage Therapeutics has faced significant setbacks, losing 90% of its value, but still holds potential with Zurzuvae, the only FDA-approved treatment for postpartum depression. Despite recent failures ...